Enterococcus faecalis ( E. faecalis ) is an opportunistic pathogen associated with severe infections, particularly in hospital settings. Increasing antibiotic resistance and diverse virulence factors highlights the urgent need for innovative, effective therapeutic approaches. In this study, a lactoferrin–Bismuth Nanoform (LF-Bi-NF) was synthesized and comprehensively characterized using UV–visible spectroscopy, scanning electron microscopy (SEM), energy-dispersive X-ray (EDX) mapping, dynamic light scattering (DLS), and Fourier-transform infrared (FTIR) spectroscopy. However, gamma radiation negatively impacted the stability of LF-Bi-NF. The LF-Bi-NF was evaluated against pathogenic E. faecalis isolates through in vitro assays, in addition to in vivo investigations in orally infected mice. The LF-Bi-NF exhibited antibacterial activity, with inhibition zones of 20.0 ± 0.10, 21.0 ± 0.15, 18.0 ± 0.25, and 15.0 ± 0.31 mm against E. faecalis _1, E. faecalis _2, E. faecalis _3, and E. faecalis ATCC 29212, respectively. While both lactoferrin and bismuth salts alone exhibited no detectable activity. The LF-Bi-NF demonstrated minimum inhibitory concentrations (MICs) of 3.125, 1.56, 6.25, and 12.5 µg/mL and minimum bactericidal concentrations (MBCs) of 12.50, 3.125, 25, and 25 µg/mL against the respective isolates, along with inhibition of biofilm formation at sub-MIC levels. Mechanistic investigations indicated disruption of cell wall integrity, increased membrane permeability, and protein leakage, particularly in the strong biofilm-forming isolate E. faecalis _2. Additionally, gene expression analysis showed that the antibiotic resistance associated genes norA, ermC , and EF3314 were downregulated by 64%, 59%, and 87%, respectively. In vivo studies demonstrated that LF-Bi-NF treatment promoted recovery in infected mice, improved immunological biomarkers (IL-12, IL-10, MPO, and IFN-γ), and significantly reduced bacterial burden in the bloodstream to undetectable levels within four days. In conclusion, LF-Bi-NF represents a promising nano-therapeutic candidate for the treatment of E. faecalis infections, exhibiting strong antibacterial, anti-biofilm, anti-virulence, and immunomodulatory properties.